Home › All Companies › ALZN › Current Report

Alzamend Neuro, Inc. (ALZN) — Current Report

AI-Powered SEC Filing Analysis

← All ALZN filings
Latest Current Report Filed: 2026-04-17

Key Insights

  • Alzamend Neuro held its annual shareholder meeting and the stockholders voted on key proposals, including the election of directors and approval of the 2025 Stock Incentive Plan.
  • The company received shareholder approval to implement a reverse stock split, which could potentially improve stock liquidity and market perception.
  • Shareholders approved the ratification of the independent registered public accounting firm for the upcoming fiscal year.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-04-17. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-20
  • Alzamend Neuro, Inc. (ALZN) received a notice from Nasdaq indicating that the company's stockholders' equity did not meet the minimum $2.5 million requirement for continued listing on the Nasdaq Capital Market.
  • The company has been given 45 days to submit a plan to regain compliance, and if accepted, may have up to 180 days to evidence compliance.
  • There is no assurance that the company's plan will be accepted or that it will be able to regain compliance, and failure to do so could result in delisting of the company's common stock.
Sentiment: Negative Significance: 7/10
View Original Filing →
Filed: 2026-03-06
  • Alzamend Neuro, Inc. has entered into an at-the-market (ATM) equity offering program, allowing them to raise up to $3 million in additional capital to fund their operations.
  • The ATM offering will be made under Alzamend's existing shelf registration statement, providing flexibility to access the capital markets as needed.
  • Ascendiant Capital Markets, LLC has been appointed as the sales agent, indicating the company's efforts to secure additional financing to support its business initiatives.
Sentiment: Positive Significance: 6/10
View Original Filing →

Other reports for Alzamend Neuro, Inc.

Insider Trading Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.